Physician profile
Steven L Kanner
NPI 1053306969
$2,026.30
in general payments reported to CMS, 2019-2025
30 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $282 · 2021: $364 · 2022: $173 · 2023: $217 · 2024: $246 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $226.97 | 2019-2021 | |
| Abbvie INC. | $195.32 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $176.91 | 2023-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $148.03 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $127.23 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $114.52 | 2019-2020 | |
| Pfizer INC. | $99.60 | 2019-2023 | |
| Amgen INC. | $93.47 | 2024-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $84.72 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.40 | 2022-2024 | Xifaxan |
| Lilly USA, LLC | $74.52 | 2022-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $71.45 | 2021-2022 | |
| Allergan, INC. | $60.93 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.06 | 2022 | |
| Horizon Therapeutics Plc | $46.57 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $46.30 | 2023 | Cologuard Collection Kit |
| Abiomed | $41.33 | 2025 | |
| Lundbeck LLC | $37.86 | 2024-2025 | Rexulti |
| Esperion Therapeutics, INC. | $36.72 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.03 | 2025 | Caplyta |
| Gilead Sciences, INC. | $24.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.47 | 2021 | |
| Almatica Pharma LLC | $22.23 | 2021 | |
| Abbott Laboratories | $21.66 | 2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $21.27 | 2023 | Lyvispah |
| Forte Bio-Pharma LLC | $20.13 | 2025 | Prolate, Nalocet, Tanlor |
| Bausch Health US, LLC | $17.71 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.23 | 2021 | |
| Organogenesis INC. | $14.90 | 2021 | |
| Biodelivery Sciences International, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.